4/A: Sana Biotechnology Director Douglas G. Cole Corrects Option Shares Acquisition in Amended SEC Filing

Douglas G. Cole, a director at Sana Biotechnology, files an amended Form 4/A to correct the number of option shares acquired on June 6, 2024.

Summary

• Douglas G. Cole, a director of Sana Biotechnology, Inc., filed an amended Form 4/A with the SEC to correct a clerical error regarding the number of option shares acquired.
• The original transaction occurred on June 6, 2024, and the amendment was filed on July 15, 2024.
• The correction pertains to a stock option granting the right to buy 65,000 shares of Sana Biotechnology's common stock at an exercise price of $7.36.
• The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of stockholders, contingent upon continuous service to Sana through that date.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a clerical error. It doesn't indicate significant positive or negative news, but accuracy in reporting is always viewed favorably.

Future Outlook

The options vest and become exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. ('Sana'), provided that the reporting person provides continuous service to Sana through such date.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry.

Key Dates